Thyroid in neonates

Reading File

Finding Sources

Searching PubMed

congenital hypothyroidism neonatal screening

Reading File

I now have comprehensive information. Let me compile the full answer:

Thyroid in Neonates

1. Fetal Thyroid Development

The thyroid gland originates at week 3 of gestation from endodermal cells at the base of the tongue between the first and second pharyngeal pouch. The thyroid diverticulum descends to its pretracheal position between 5–7 weeks, with bilobar division at ~5 weeks. Parafollicular C-cells arise from the ultimobranchial bodies (4th and 5th pouches) and form Zückerkandl's tubercle. The thyroglossal duct degenerates by week 10 — incomplete degeneration causes thyroglossal duct cysts or pyramidal lobe.

Key developmental milestones:

Gestational Age	Event
Week 3	Thyroid primordium forms
Weeks 5–7	Descent to pretracheal position
Weeks 10–12	Hypothalamic/pituitary-vascular maturation; TRH detectable
Weeks 12–14	Active iodide trapping; TH synthesis begins (TPO, NIS, Tg expressed)
Weeks 18–20	TH secretion, TSH, and T4 rise significantly
Week 20	T4 ~2 μg/dL
Term	T4 reaches adult levels (~10 μg/dL)
Before 16 weeks	Fetus entirely dependent on maternal TH

Fetal T3 is negligible until week 30 due to high D3:D1 deiodinase ratio (T4 preferentially converted to reverse T3). Near term, T3 rises to ~50 ng/dL. At birth, 30–50% of T4 in cord blood is of maternal origin, providing partial protection to fetuses with congenital hypothyroidism.

2. Normal Neonatal Thyroid Physiology

Immediately after birth:

TSH surges (neonatal TSH surge) within minutes of delivery, driven by cold exposure and TRH
This triggers a rise in T4 conversion to T3
T4 levels transiently rise (transient hyperthyroxinemia may reflect thermogenesis adaptation)
TSH normalizes to adult levels within a few days via T3/T4 negative feedback
T4 and T3 return to normal adult values within 4–6 weeks
The hypothalamic-pituitary-thyroid (HPT) axis fully matures at 1–2 months after birth

In premature neonates (<28 weeks):

HPT axis is immature; the physiological TSH surge is dramatically lower or absent
FT4 and FT3 are low with paradoxically normal TSH
Takes 3–8 weeks to reach levels similar to term infants
Transient hypothalamic hypothyroidism of prematurity occurs in up to 50% of infants born <28 weeks
Dopamine (used in NICU) can suppress TSH release further

3. Congenital Hypothyroidism (CH)

Incidence

Estimated 1 in 2,000–4,000 newborns (higher with sensitive TSH cut-offs)
Higher incidence in Asians, Hispanics, premature infants, and older mothers
Prior to newborn screening, estimated at 1 in 7,000

Classification

Permanent CH (75–86%) — requires lifelong treatment:

Thyroid dysgenesis (85%): agenesis, ectopy, or hypoplasia
Dyshormonogenesis (15%): structurally normal gland with hormone synthesis defect

Transient CH — resolves within weeks to months:

Endemic iodine deficiency (most common worldwide)
Maternal antithyroid drug exposure
Transfer of maternal TSH-receptor blocking antibodies
Maternal iodine excess (e.g., amiodarone, contrast media)
Liver hemangiomas (excess deiodinase 3 activity)
Certain genetic defects

Central (Secondary/Tertiary) CH: 1 in 25,000–50,000 newborns — hypothalamic/pituitary deficiency

Causes by Category (Harrison's, 2025)

Thyroid dysgenesis: 65%
Dyshormonogenesis (inborn errors of TH synthesis): 30%
TSH-receptor antibody mediated: 5%
Developmental abnormalities twice as common in girls

4. Genetics of Congenital Hypothyroidism

Defective Gene	Type	Inheritance	Consequence
TTF-1 (TITF-1)	Dysgenesis	Heterozygous LOF	Thyroid hyperplasia, choreoathetosis, pulmonary problems
TTF-2 (FOXE-1)	Dysgenesis	Homozygous recessive	Thyroid agenesis, choanal atresia, spiky hair
PAX-8	Dysgenesis	Heterozygous LOF	Thyroid dysgenesis, kidney abnormalities
NKX2-1	Dysgenesis	Heterozygous LOF	Thyroid + brain + lung abnormalities
NKX2-5	Dysgenesis	Heterozygous LOF	Thyroid + heart abnormalities
GLIS3	Dysgenesis	Homozygous recessive	Thyroid dysgenesis + neonatal diabetes + facial abnormalities
TSH receptor	Dyshormonogenesis	Homozygous recessive	Resistance to TSH
NIS (SLC5A5)	Dyshormonogenesis	Homozygous recessive	Inability to transport iodide
DUOX2/DUOXA2	Dyshormonogenesis	AR / Heterozygous LOF	Organification defect
TPO	Dyshormonogenesis	Homozygous recessive	Organification defect
PROP-1, PIT-1	Central	Homozygous recessive	Combined pituitary hormone deficiencies
IGSF1	Central	X-linked LOF	Loss of TSH-R expression, testicular enlargement

Dyshormonogenesis: autosomal recessive. Thyroid dysgenesis: only ~2% of cases are inherited; most are sporadic (polygenic/epigenetic).

5. Clinical Features

Early signs (often absent at birth due to maternal TH protection):

Lethargy, increased sleep
Prolonged neonatal jaundice
Myxedematous facies
Large anterior fontanelle
Macroglossia
Distended abdomen, umbilical hernia
Hypothermia, hypotonia

Late signs (if untreated):

Poor sucking and feeding difficulties
Constipation
Developmental delay
Cognitive and growth retardation
Myxedema
Decreased activity

Important: 10% of CH infants have other congenital defects; of these, 50% have congenital heart defects.

6. Neonatal Screening

Newborn screening is universal in the US and most industrialized countries. Worldwide, ~25% of all newborns are screened.

Timing: Ideally days 2–4 of life for term infants; within 7 days for preterm infants. Children discharged on day 1 may be sampled at that time.

Screening strategies:

TSH first (most common) → reflex T4 if TSH elevated: misses central hypothyroidism
T4 first → reflex TSH if T4 low
Combined TSH + FT4 ± Tg: differentiates primary vs. central causes

Filter paper heel prick → mailed to central lab. Each program has its own cut-off values.

Pitfalls:

False-positive TSH elevations in the first 2 days of life (physiologic TSH surge)
Transplacental maternal TSH heterophile antibodies → false-positive TSH
Premature/acutely ill infants: late TSH rise → may be missed on first sample → many programs do a second screen
Dopamine suppresses TSH in NICU infants
Seasonal variation: false-positive rate higher in winter (0.9%) vs. summer (0.6%)

Confirmatory testing (serum): TSH + free T4 (or total T4), age-specific reference intervals. Further workup includes radionuclide thyroid scan, thyroid ultrasound, and serum thyroglobulin — but must not delay treatment.

7. Treatment

Levothyroxine (LT4) is the treatment of choice
Goal: normalize serum TSH and raise T4 to age-appropriate levels
If started within the first 2 weeks of life → prevents mental retardation in >90% of children
Dose is weight-based and adjusted as the infant grows

8. Neonatal Graves Disease

If the mother has Graves disease, stimulatory TSH-receptor antibodies (TSI/TRAb) can cross the placenta and stimulate the fetal/neonatal thyroid, causing:

Fetal/neonatal hyperthyroidism
Thyrotoxicosis, tachycardia, goiter, advanced bone age

Measurement of TSH-receptor antibodies (thyroid-stimulating Ig assay) during pregnancy is useful for risk assessment. The condition is transient as maternal antibodies are cleared.

Sources:

Creasy & Resnik's Maternal-Fetal Medicine, Ch. 61
Tietz Textbook of Laboratory Medicine, 7th Ed., Ch. 26
Harrison's Principles of Internal Medicine, 22nd Ed. (2025), Ch. 395

Meromelia in neonates causes

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Reading File

Finding Sources

Searching Images

meromelia phocomelia limb reduction defect neonate

I now have comprehensive data. Here is the complete answer:

Meromelia in Neonates — Causes

Definition

Meromelia (Greek: meros = part, melos = limb) refers to partial absence of one or more limbs. It is a type of limb reduction defect that includes:

Hemimelia — absence of a specific bone segment (e.g., absent fibula)
Phocomelia — hands/feet attached directly to the trunk by small, irregularly shaped bones ("seal limbs")
Micromelia — all segments present but abnormally short (sometimes classified separately)

It differs from amelia (complete absence of a limb). Major limb defects occur in approximately 1 in 500 neonates.

Neonatal X-ray showing meromelia and phocomelia

Critical Period

The critical period for limb development is 24–36 days after fertilization (approximately 5th–6th week of gestation). Any insult during this window can disrupt limb formation. Insults early in the critical period tend to produce severe defects (amelia); insults later cause partial absence (meromelia).

Causes

1. Teratogenic (Drug/Chemical) Causes

Teratogen	Mechanism	Features
Thalidomide	Inhibits early blood vessel formation in limb buds; also disrupts FGF and angiogenesis	Classic cause; ~12,000 neonates affected 1957–1962; phocomelia, absent/short long bones; associated with anotia/microtia, cardiac defects, intestinal atresia
Warfarin	Disrupts vitamin K-dependent bone proteins	Stippled epiphyses, limb hypoplasia
Phenytoin	Disrupts folate metabolism and cell proliferation	Digit/limb hypoplasia (fetal hydantoin syndrome)
Valproic acid	Folic acid antagonism	Limb reduction, neural tube defects
Cocaine	Vascular disruption → ischemia	Limb reduction defects, other defects
Misoprostol	Vascular disruption	Möbius sequence, transverse limb defects
Alcohol	Multifactorial disruption	Part of fetal alcohol spectrum

Thalidomide is the classic cause. The sensitive period was 20–36 days after fertilization. Currently still used for leprosy, multiple myeloma, and autoimmune diseases — absolutely contraindicated in women of childbearing age. Teratogen-induced meromelia is usually bilateral and symmetric.

2. Genetic / Chromosomal Causes

Chromosomal:

Trisomy 18 (Edwards syndrome) — associated with various limb malformations
Other chromosomal aneuploidies

Mutant genes / Monogenic causes:

Mutations in HOX genes (HOXA/HOXD family) — master regulators of limb patterning along the proximal-distal and anterior-posterior axes
BMP (bone morphogenetic proteins) pathway mutations
SHH (sonic hedgehog) mutations — anterior-posterior patterning
WNT7 mutations — dorsal-ventral limb patterning
EN1 mutations
TBX5 mutations (chromosome 12q24.1) → Holt-Oram syndrome (upper limb abnormalities + congenital heart defects)
HOXA13 mutations → hand-foot-genital syndrome
HOXD13 mutations → synpolydactyly

3. Vascular Disruption / Ischemic Causes

Disruption of blood supply during limb development leads to limb reduction defects via ischemia and tissue loss. This is a key non-teratogenic, non-genetic mechanism. It explains some sporadic cases and is implicated in cocaine-associated meromelia.

4. Amniotic Band Syndrome (ABS)

Occurs in 1:1,200 to 1:15,000 live births
Fibrous bands of amnion encircle and constrict fetal limbs
Second or third trimester disruption → constriction rings, lymphedema, and limb amputation (producing transverse meromelia)
First trimester disruption → craniofacial and visceral defects
Most commonly affects hands/feet (90%), umbilical cord (30%), abdomen (20%)
Results in: limb/digit amputation, constriction rings, acrosyndactyly (distal digit fusion)
ABS-related defects are typically asymmetric and random (unlike teratogen-induced defects)

Neonate with bilateral upper limb meromelia

5. Mechanical / Intrauterine Factors

Oligohydramnios — reduced amniotic fluid commonly associated with limb deformations (compression effects)
Intrauterine constraint and mechanical pressure during the critical developmental window

6. Multifactorial / Unknown

A combination of genetic predisposition and environmental triggers
Most cases of thyroid dysgenesis and limb defects occurring sporadically may have polygenic/epigenetic components
Many cases remain idiopathic despite full workup

Summary Table

Category	Examples	Symmetry
Teratogens	Thalidomide, cocaine, misoprostol, warfarin, phenytoin, valproate	Usually bilateral/symmetric
Genetic/Chromosomal	HOX, BMP, SHH mutations; Trisomy 18; Holt-Oram	Variable
Vascular disruption	Ischemia in utero	Variable
Amniotic band syndrome	Band constriction/amputation	Asymmetric/random
Mechanical	Oligohydramnios, compression	Variable

Sources:

The Developing Human: Clinically Oriented Embryology — Ch. 16 (Birth Defects of Limbs), Ch. 20 (Teratology)
Langman's Medical Embryology — Ch. 12 (Limb Defects)
Creasy & Resnik's Maternal-Fetal Medicine — Ch. 26 (Amniotic Band Syndrome)

This is a shared conversation. Sign in to Orris to start your own chat.